IMATINIB RESISTANCE MUTATION ANALYSIS; IRMA
Imatinib is a Tyrosine kinase inhibitor (TKI) capable of inducing durable hematologic and cytologic remissions in patients with Chronic Myeloid Leukemia (CML). Unfortunately a significant subset of patients develop functional resistance to TKI. Recognition of this resistance is important in CML as the effect of some mutations can be overcome by Imatinib dosage.
Parameter(s) covered : 1
Report Frequency: Sample Mon by 11 am; Report Sat
Special Instruction: Submit latest BCR-ABL Quantitative report along with sample.
Price : ₹ 8400.00
Parameters
- REPORT ATTACHED